72 related articles for article (PubMed ID: 28039707)
1. FcγRIIa-H131R variant is associated with inferior response in diffuse large B cell lymphoma: A meta-analysis of genetic risk.
Ziakas PD; Poulou LS; Zintzaras E
J BUON; 2016; 21(6):1454-1458. PubMed ID: 28039707
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of glutathione S-transferase genotyping in patients with diffuse large B-cell lymphoma.
Atanaskovic L; Cikota-Aleksic B; Tarabar O; Trimcev J; Zivanovic-Ivic A; Marjanovic S; Magic Z
J BUON; 2016; 21(6):1459-1465. PubMed ID: 28039708
[TBL] [Abstract][Full Text] [Related]
3. Correlation of FcγRIIIa Polymorphisms to the Response of Rituximab in Thai Patients with Diffuse Large B-Cell Lymphoma.
Angsirisak N; Wittayalertpanya S; Limpanasithikul W; Bunworasate U; Owattanapanich D
J Med Assoc Thai; 2015 Dec; 98(12):1215-21. PubMed ID: 27004307
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
5. FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.
Ghesquières H; Larrabee BR; Haioun C; Link BK; Verney A; Slager SL; Ketterer N; Ansell SM; Delarue R; Maurer MJ; Fitoussi O; Habermann TM; Peyrade F; Dogan A; Molina TJ; Novak AJ; Tilly H; Cerhan JR; Salles G
Hematol Oncol; 2017 Dec; 35(4):447-455. PubMed ID: 27282998
[TBL] [Abstract][Full Text] [Related]
6. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
7. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
8. The impact of Fc gamma receptor IIa and IIIa gene polymorphisms on the therapeutic response of rituximab in Egyptian adult immune thrombocytopenic purpura.
Ellithy HN; Ahmed SH; Shahin GH; Matter MM; Talatt M
Hematology; 2018 Apr; 23(3):169-174. PubMed ID: 28856973
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of rituximab therapy on diffuse large B-cell lymphoma with different Fcgamma RIIIA gene polymorphisms: a prospective study].
Zhang W; Wang X; Duan MH; Li J; Zhou DB
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(6):400-2. PubMed ID: 19567119
[TBL] [Abstract][Full Text] [Related]
10. Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.
Keane C; Nourse JP; Crooks P; Nguyen-Van D; Mutsando H; Mollee P; Lea RA; Gandhi MK
Intern Med J; 2012 Oct; 42(10):1113-9. PubMed ID: 21883784
[TBL] [Abstract][Full Text] [Related]
11. FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.
Paiva M; Marques H; Martins A; Ferreira P; Catarino R; Medeiros R
Cancer Genet Cytogenet; 2008 May; 183(1):35-40. PubMed ID: 18474295
[TBL] [Abstract][Full Text] [Related]
12. Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.
Burkhardt B; Yavuz D; Zimmermann M; Schieferstein J; Kabickova E; Attarbaschi A; Lisfeld J; Reiter A; Makarova O; Worch J; Bonn BR; Damm-Welk C
Ann Hematol; 2016 Sep; 95(9):1503-12. PubMed ID: 27376362
[TBL] [Abstract][Full Text] [Related]
13. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
14. Genetic linkage and association of Fcgamma receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus.
Edberg JC; Langefeld CD; Wu J; Moser KL; Kaufman KM; Kelly J; Bansal V; Brown WM; Salmon JE; Rich SS; Harley JB; Kimberly RP
Arthritis Rheum; 2002 Aug; 46(8):2132-40. PubMed ID: 12209518
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
16. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Warzocha K; Michallet AS; Robak T; Coiffier B; Salles G
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):131-41. PubMed ID: 20191326
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.
Ma Y; Zhang P; Gao Y; Fan H; Zhang M; Wu J
Int J Clin Exp Pathol; 2015; 8(11):14875-84. PubMed ID: 26823817
[TBL] [Abstract][Full Text] [Related]
18. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
[TBL] [Abstract][Full Text] [Related]
19. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy.
Hatjiharissi E; Hansen M; Santos DD; Xu L; Leleu X; Dimmock EW; Ho AW; Hunter ZR; Branagan AR; Patterson CJ; Kortsaris A; Verselis S; Fox E; Treon SP
Clin Lymphoma Myeloma; 2007 Jan; 7(4):286-90. PubMed ID: 17324336
[TBL] [Abstract][Full Text] [Related]
20. The impact of
Rožman S; Novaković S; Grabnar I; Cerkovnik P; Novaković BJ
Oncol Lett; 2016 May; 11(5):3332-3336. PubMed ID: 27123112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]